Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability and Bioavailability of Crizotinib Pediatric Microspheres
NCT03978143Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crizotinib in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumor (IMT) and 1 more (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 96 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration at 96 hours and 5 more. Started Jun 2019; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic large cell lymphoma (ALCL)inflammatory myofibroblastic tumor (IMT)Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03978143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978143.